Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01088243 · ClinicalTrials.gov registry record · Phase 1
Targeting Oxidative Stress in Chronic Beryllium Disease
A Phase 1 study, sponsored by National Jewish Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01088243 is a Phase 1 study that has completed, run by National Jewish Health. The registered enrollment target is 18 participants.
The verdict
NCT01088243, a Phase 1 study, has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to understand if a drug called mesalamine helps to control inflammation associated with chronic beryllium disease (CBD). We hypothesize that in CBD subjects treated with prednisone, mesalamine treatment will enhance the immunosuppressive effects of prednisone, and thus reduce the immune response to beryllium.
Interventions
- DRUG Placebo
- DRUG Mesalamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01088243
The ClinicalTrials.gov registry entry for NCT01088243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01088243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01088243 about?
NCT01088243 is a clinical study titled "Targeting Oxidative Stress in Chronic Beryllium Disease". The purpose of this study is to understand if a drug called mesalamine helps to control inflammation associated with chronic beryllium disease (CBD). We hypothesize that in CBD subjects treated with prednisone, mesalamine treatment will enhance the immunosuppressive effects of prednisone, and thus r...
What is the current status of trial NCT01088243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2010-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01088243?
The interventions under investigation include: Placebo (DRUG), Mesalamine (DRUG).
Who is sponsoring clinical trial NCT01088243?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.